International Consensus Statement News Today : Breaking News, Live Updates & Top Stories | Vimarsana

COPENHAGEN, Denmark, April 24, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the United Kingdom’s Medicines & Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for YORVIPATH® (palopegteriparatide; developed as TransCon™ PTH) in Great Britain as a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism, and has also granted YORVIPATH orphan drug status. YORVIPATH is a prod

The latest study included 148,000 individuals in Sweden who were diagnosed with ADHD. The researchers noted that starting ADHD medications reduced their overall mortality risk, particularly from

COPENHAGEN, Denmark, Jan. 31, 2024 -- Ascendis Pharma A/S today announced that YORVIPATH® , a parathyroid hormone replacement therapy indicated for the treatment of adults with chronic...

The emergence of SARS-CoV-2 has brought olfactory dysfunction to the forefront of public awareness, because up to half of infected individuals could develop olfactory dysfunction. Loss of smell—which can be partial or total—in itself is debilitating, but the distortion of sense of smell (parosmia) that can occur as a consequence of a viral upper respiratory tract infection (either alongside a reduction in sense of smell or as a solo symptom) can be very distressing for patients. Incidence of olfactory loss after SARS-CoV-2 infection has been estimated by meta-analysis to be around 50%, wit...

In a statement Wednesday, the Concussion in Sport Group, a panel of the world’s leading experts on concussion and head trauma, stopped short of definitively linking the brain disease CTE with repeated head trauma.